The Current Situation. A. The Present Issues
The Current Situation. While a large number of ARV drugs currently in use are under patent, most of these drugs can be made available on the international market as less expensive generics. Moreover, at least nine ARVs are due to come off-patent by 2010.6 Although the numbers are increasing slowly, few developing countries have the technical capacity or the resources to produce generic varieties of ARV drugs. Even though patent protection of ARVs in developing countries has taken place in an ad hoc fashion, with the increasing com- pliance of developing countries to the provisions of TRIPS, brand name drug companies are beginning to be able to patent their products in more countries. In addition, a number of Least Developed Countries (LDCs) have already enacted legislation which extends patent protection to pharmaceutical products de- spite being exempted from having to afford patent protection to pharmaceutical products until 2016.7 Two primary developments with the World Trade Organization (WTO) have played a role in expediting the availability of generic ARVs: the landmark Doha Declaration on TRIPs and Public Health (Doha Declara- tion) and the WTO General Council Decision of 30 August 2003 (30 August Decision). The Doha Declara- tion clarified once and for all, the debate around the ability of developing countries to issue compulsory licenses where necessary, in the interests of public health. As such it was a turning point for developing and least-developed countries which have the capacity to manufacture generic drugs. While this was a significant step, the reality is that most developing countries do not have a sufficiently large manufactur- ing industry to satisfy the demand for generic drugs in their own countries. This meant that a pathway to access generic drugs for countries with insufficient manufacturing capacity remained elusive. For that reason, a deadline was set by WTO members (for the end of 2002) by which a solution should be found for these countries to have a way to access essential medicines.
The Current Situation. 2.1 Cabinet resolved to agree the signing of a new development agreement for the Royal Sands site at its meeting on 26th July 2012. This decision was called in by Scrutiny for consideration at its meeting on 16th August, and as a result of which three recommendations were made to Cabinet. These recommendations were considered by Cabinet at its meeting on 23rd August but Cabinet reconfirmed its original decision.
The Current Situation. 2.1 The Agreements between the authorities which include the Joint Transportation Boards Terms of Reference are usually reviewed every four years. This period has now lapsed and a new agreement is required to be put in place, as previously indicated there have been some amendments to the agreement.
The Current Situation. This RM6094 Spark DPS Agreement is a new offering from CCS. Having reviewed our approach to emerging technologies we are pursuing a new approach for immature markets that enables Customers access to genuine innovation and Suppliers a route to market which is adaptable as their capabilities change. Outside of the cloud software and services at present CCS does not have any commercial offerings associated with the provision of new products emerging from technology innovation, such as those developed as proof of concepts between a public sector customer and a supplier. This DPS will form one part of a wider programme of work to provide advice and guidance to Customers in order to ensure the right commercial and Supplier relationship approaches to innovation are being taken and that barriers to successful exploitation of innovation are not unnecessarily created. This includes a focus on a collaborative relationship and a balanced approach to risk within the contract.
